BION

Created with European participation, BION sees its main goal as raising the level of laboratory diagnostics received by Russian patients to the world level. Therefore, the priorities in our work are the issues of maintaining the regulatory quality of research, increasing the volume and importance of diagnostic information, organizing a high level of service, optimizing interaction between medical institutions and a centralized laboratory.

History

2023: Transfer to Protek ownership

Protek Group of Companies bought from the main shareholder of VSMPO-Avisma Corporation Mikhail Shelkov the assets of the chemical-pharmaceutical company Bion. This became known in early February 2023.

Bion specializes in the production of pharmaceutical substances for the production of finished forms of medicines. The range includes antioxidants, anastetics, beta-blockers, anticoagulants, antitumor and antiviral agents, etc. The company also conducts joint research programs with Russian and foreign chemical enterprises and institutions. In particular, new laboratory and industrial methods of fine organic synthesis are being developed.

Protek bought the manufacturer of pharmaceutical substances from the main owner of VSMPO-Avisma

According to the Vedomosti newspaper, the sale of Bion was closed on February 2, 2023: it included three legal entities of the company - Bion LLC, Himfarmkomplekt LLC and Pharmtellect LLC. Himpharmkomplekt specializes in the production of other basic organic chemicals. Pharmintellect, in turn, is engaged in the wholesale of pharmaceuticals. The amount of the transaction was not disclosed. According to market participants, the value of all three assets can vary from 4.2 billion rubles. up to 6 billion rubles. excluding credit burden and other obligations.

The Protek group of companies already includes a network of Atlas personalized medicine clinics and two pharmaceutical companies specializing in the production of injectable drugs, Sotex and Rafarma. On the basis of the assets of Bion, it is planned to develop a business for the manufacture of substances. In the context of the dependence of the Russian market on imported active substances, the work of Bion will not be limited only to the needs of Protek's own enterprises - the company intends to cooperate with other industry players.^[1]

Notes